GENEDX HOLDINGS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.61 USD | -3.83% |
|
-4.81% | +613.09% |
| Apr. 30 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
| Apr. 30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +613.09% | 513M | - | ||
| -24.16% | 7.76B | B+ | ||
| +68.65% | 4.33B | C+ | ||
| -2.98% | 2.64B | - | ||
| +2.72% | 2.63B | B- | ||
| -46.17% | 2.16B | B- | ||
| -22.12% | 1.46B | A- | ||
| +13.62% | 1.17B | B+ | ||
| -43.81% | 1.14B | C+ | ||
| +20.41% | 999M | B- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WGS Stock
- Ratings GeneDx Holdings Corp.
